Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TRIB 
Trinity Biotech plc (TRIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: TRIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.55% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.89M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 0.5 | 52 Weeks Range 0.48 - 1.97 | Updated Date 11/15/2025 |
52 Weeks Range 0.48 - 1.97 | Updated Date 11/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.64% | Operating Margin (TTM) -42.73% |
Management Effectiveness
Return on Assets (TTM) -10.53% | Return on Equity (TTM) -1913.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 117955422 | Price to Sales(TTM) 0.37 |
Enterprise Value 117955422 | Price to Sales(TTM) 0.37 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 18632019 | Shares Floating 325113826 |
Shares Outstanding 18632019 | Shares Floating 325113826 | ||
Percent Insiders 12.01 | Percent Institutions 65.77 |
Upturn AI SWOT
Trinity Biotech plc
Company Overview
History and Background
Trinity Biotech plc was founded in 1991. It is a leading developer and manufacturer of diagnostic products for the detection of infectious diseases and autoimmune disorders. The company has grown through both internal development and strategic acquisitions, expanding its product portfolio and global reach.
Core Business Areas
- Diagnostic Reagents: Trinity Biotech develops and manufactures a wide range of diagnostic reagents and test kits. These products are used in clinical laboratories, hospitals, and blood banks worldwide for the diagnosis and monitoring of various medical conditions.
- Diagnostic Instrumentation: The company also offers diagnostic instrumentation, including automated immunoassay analyzers and point-of-care testing devices, designed to complement their reagent offerings and improve laboratory efficiency.
Leadership and Structure
Trinity Biotech plc operates with a management team led by a CEO and a Board of Directors. The company's structure is organized around its product development, manufacturing, sales, and marketing functions.
Top Products and Market Share
Key Offerings
- Description: Trinity Biotech offers a comprehensive line of HIV diagnostic tests, including screening and confirmatory assays. These tests are critical for public health initiatives and patient care. Competitors include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Bio-Rad Laboratories.
- Product Name 1: HIV Diagnostic Assays
- Description: The company provides diagnostic solutions for the detection of Hepatitis B and C viruses. These assays are essential for early diagnosis and treatment of viral hepatitis. Key competitors include those listed for HIV diagnostics.
- Product Name 2: Hepatitis Diagnostic Assays
- Description: Trinity Biotech has a strong portfolio of tests for autoimmune disorders, such as rheumatoid arthritis and celiac disease. These tests help physicians diagnose and manage complex autoimmune conditions. Competitors include Quest Diagnostics, LabCorp, and specialized autoimmune diagnostic companies.
- Product Name 3: Autoimmune Diagnostic Assays
Market Dynamics
Industry Overview
The in-vitro diagnostics (IVD) market is characterized by significant growth driven by increasing prevalence of chronic diseases, aging populations, advancements in diagnostic technology, and growing demand for personalized medicine and point-of-care testing. The market is competitive and highly regulated.
Positioning
Trinity Biotech is positioned as a specialized provider of diagnostic solutions, focusing on infectious diseases and autoimmune disorders. Its strengths lie in its established product lines and a growing global distribution network. The company competes with larger, more diversified diagnostic companies.
Total Addressable Market (TAM)
The global in-vitro diagnostics market is projected to reach hundreds of billions of USD in the coming years. Trinity Biotech operates within specific segments of this market, such as infectious disease diagnostics and autoimmune diagnostics, which themselves represent substantial market sizes. The company's market share within these niche segments is a key factor in its revenue generation.
Upturn SWOT Analysis
Strengths
- Established product portfolio in key diagnostic areas.
- Global distribution network.
- Expertise in immunoassay technology.
- Focus on niche but critical diagnostic segments.
Weaknesses
- Limited diversification compared to larger competitors.
- Reliance on a few key product lines.
- Potential challenges in scaling manufacturing to meet rapid demand increases.
- Brand recognition may be lower than major players.
Opportunities
- Expansion into emerging markets with growing healthcare infrastructure.
- Development of new diagnostic tests for emerging infectious diseases.
- Strategic partnerships and collaborations.
- Leveraging point-of-care diagnostics market growth.
Threats
- Intense competition from larger diagnostic companies.
- Regulatory hurdles and approval processes.
- Price pressures from healthcare systems.
- Rapid technological advancements requiring continuous R&D investment.
- Global economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY - OTC)
- Siemens Healthineers AG (SIEGY - OTC)
- Bio-Rad Laboratories, Inc. (BIO)
- Quest Diagnostics Incorporated (DGX)
- Laboratory Corporation of America Holdings (LH)
Competitive Landscape
Trinity Biotech's competitive advantages lie in its specialized product focus and established presence in niche diagnostic areas. However, it faces challenges from larger, more diversified companies with greater R&D budgets, broader product portfolios, and stronger global marketing and sales capabilities. Its agility in responding to specific market needs can be an advantage.
Growth Trajectory and Initiatives
Historical Growth: Trinity Biotech plc has demonstrated growth over the years, driven by its product innovation and market expansion. However, the pace of growth can be influenced by market conditions and competitive pressures.
Future Projections: Future growth projections for Trinity Biotech plc would typically be based on analyst estimates, which consider the company's pipeline, market trends, and strategic initiatives. These projections can vary significantly.
Recent Initiatives: Recent initiatives may include the launch of new diagnostic tests, expansion into new geographic markets, or strategic partnerships aimed at enhancing its product offerings and market penetration.
Summary
Trinity Biotech plc is a specialized diagnostics company with a strong product portfolio in infectious diseases and autoimmune disorders. Its established distribution network is a key strength, but it faces intense competition from larger players. Growth opportunities exist in emerging markets and new diagnostic areas, though the company must navigate regulatory challenges and technological advancements to maintain its competitive edge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company financial reports (e.g., 10-K, Annual Reports)
- Industry research reports
- Financial news and analysis websites
- Company investor relations website
Disclaimers:
This JSON output is generated based on publicly available information and analysis. It is intended for informational purposes only and does not constitute financial advice. Market share data and projections are estimates and can vary. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trinity Biotech plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-08-18 | President, CEO, Company Secretary & Director Mr. John Gillard | ||
Sector Healthcare | Industry Medical Devices | Full time employees 401 | Website https://www.trinitybiotech.com |
Full time employees 401 | Website https://www.trinitybiotech.com | ||
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.